Tsz Isabel Wong, NP
Nurse Practitioner · New York, NYNPI 1144626508
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $18,716 of the $25,181 with a category attached, or 74.3%. It is spread thinly across 60 manufacturers, the largest accounting for just 21.8%. 2025 is the largest year on record at $11,650, more than ten times the $25 reported in 2021. Among nurse practitioner clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 758 payments — averaging $33.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Agios Pharmaceuticals, Inc.$5K
- Johnson & Johnson$2K
- Astellas Pharma US Inc$1K
- Daiichi Sankyo Inc.$1K
- Novo Nordisk$943
- E.r. Squibb & Sons, L.L.C.$856
- plus $14K from 54 others
What the payments were for
- Consulting fees$3,95716%
- Speaking & faculty fees$9454%
- Travel & lodging$2221%
- Food & beverage$18,71674%
- Education$1,2415%
- Gifts$1000%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$25,181 in reported general payments places this provider in the 95th percentile of 4,112 nurse practitioner providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TagrissoOsimertinib Mesylate | 64 | $1,116,477 |
| ReblozylLuspatercept-Aamt | 41 | $825,104 |
| BrukinsaZanubrutinib | 13 | $195,598 |
| ProcritEpoetin Alfa | 45 | $191,858 |
| Abiraterone Acetate | 77 | $148,884 |
| Somatuline DepotLanreotide Acetate | 13 | $124,937 |
| FarxigaDapagliflozin Propanediol | 113 | $108,188 |
| RybelsusSemaglutide | 54 | $88,675 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 93 | $59,093 |
| JardianceEmpagliflozin | 49 | $45,749 |
| Diclofenac Sodium | 109 | $36,954 |
| JanuviaSitagliptin Phosphate | 26 | $29,388 |
| VascepaIcosapent Ethyl | 81 | $28,637 |
| EliquisApixaban | 39 | $26,802 |
| OzempicSemaglutide | 25 | $24,135 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaTagrisso, Farxiga, Breztri Aerosphere, Symbicort | $813 | $1,292,241303 claims |
| E.r. Squibb & Sons, L.L.C.Reblozyl | $856 | $825,10441 claims |
| Beigene USA, Inc.Brukinsa | $254 | $195,59813 claims |
| Johnson & JohnsonProcrit | $1,710 | $191,85845 claims |
| Ipsen Biopharmaceuticals, IncSomatuline Depot | $65 | $124,93713 claims |
| Novo NordiskRybelsus, Ozempic | $943 | $112,81079 claims |
| Boehringer IngelheimJardiance, Tradjenta | $68 | $64,23166 claims |
| PfizerEliquis, Abrysvo | $286 | $32,12556 claims |
| MerckJanuvia | $786 | $29,38826 claims |
| AmgenProlia | $130 | $22,51413 claims |
| GileadVemlidy | $521 | $22,42715 claims |
| Lilly USA, LLCMounjaro | $729 | $20,43618 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,112 nurse practitioner providers in New York.
Other nurse practitioner in New York
- Patricia McGoldrickNew York$202K
- Jodi LogerfoNew York$48K
- Aileen FerrickNew York$26K
- Chris BustamanteNew York$22K
- Mayra PozoNew York$14K
- Janet JohnsonNew York$12K
- Rachel RankinNew York$10K
- Richelle CassellNew York$10K
- Michelle DartSyracuse$95K
- Susan KreppelWilliamsville$67K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.